anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To elucidate a DNA-repairing mechanism in mammals, and to provide a method for treating and diagnosing a related disease.  &lt;P&gt;SOLUTION: The present invention relates to a nucleic acid sequence encoding human TFIIH 8kDa subunit and a related sequence. The nucleic acid can be used for a method for producing the TFIIH subunit and for a method for diagnosing or treating transcription and NER deficiency [especially in several forms of trichothiodystrophy(TTD)]. HTFB5/TTDA gene and a coded protein can be used for therapeutic or genetically therapeutic products targeting the treatment of congenital NER lesion. A molecular probe or antibody specific to TTDA can be used for a method for diagnosing lesions in the basic transcription, NER and TCR activities of mammals.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means for removing cornoid lamella without having influence on skin epidermis.  &lt;P&gt;SOLUTION: A cosmetic comprises (1) a vinyl pyrrolidone-vinyl acetate copolymer and (2) an acrylic acid starch block copolymer and/or its salt. The cosmetic is preferably a pack cosmetic and the cosmetic is particularly preferably gommage pack cosmetic. The cosmetic preferably further comprises vinyl acetate polymer emulsion and the cosmetic is particularly preferably a cosmetic for removing cornoid lamella. Cornoid lamella can be removed without having influence on the skin epidermis by carrying out gommage action on the skin by using the cosmetic.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject composition which has tyrosinase inhibitory activity and is useful in the lightening in color of the skin or the dermatological treatment of pigment stigma by including an acetone-α,α&#39;-dioxalate type compound as an active ingredient. SOLUTION: This composition contains a compound of the formula (R and R&#39; are each a 1-6C alkyl or H) or its physiologically permissible salt in a physiologically permissible medium. As the compound of the formula, diethyl acetone-α,α-dioxalate is particularly favorable. It is desirable that this composition contains the compound of the formula as an active component in the form enclosed in a ribosomal vector. Further, the active component of the formula is preferably contained in a proportion of 0.1-5 wt.% in this composition The medium used in this composition is mainly composed of water and when necessary, an auxiliary used in a cosmetic or a preparation for external use for the skin can be added. By this process, the lightening in color of the skin or the treatment and prevention of pigment stigma is expectable.
1,223,250. Two-component packs for hair treatment. L&#39;OREAL. 19 April, 1967 [19 April, 1966], No. 2326/70. Divided out of 1,197,031. Addition to 1,197,037. Heading DIP. A two-component pack for use in the treatment of hair comprises, as the first component, a methylolated compound which is monomethylol dicyandiamide, bis-methoxymethyl urea, monomethylol dimethylhydantoin, monomethylol ethyleneurea, monomethylol ethylene thiourea, dimethylol ethylene thiourea. monomethylol guanidine, monomethylol ethyl carbamate. N, N&#39;-dimethylol (2-methyl- 2-propyl) propylene bis-carbamate, dimethylol ethyl methylene-bis-carbamate, dimethylol succinamide, dimethylol adipamide. N, N-diethyl-N&#39;-methylol urea, dimethylol ethylene urea, dimethylol ethyl carbamate or tetramethylol acetylene diurea in the solid state, and, as the second component, an acid polymerisation catalyst, either or both of these components containing a solution a nitrogencontaining compound which is urea, melamine, dicyandiamide, N, N-diethyl urea, ethylene urea, isopropyl carbamate, dimethyl hydantoin, ethylene thiourea, guanidine carbamate or succinamide, or comprises, as the first component, a methylolated compound which is monomethylol urea, dimethylol urea, monomethylol thiourea, dimethylol thiourea or trimethylol melamine in the solid state, and, as the second component, an acid polymerisation catalyst, either or both of these components containing a solution of a nitrogen-containing compound which is N, N-diethylurea, ethylene urea. isopropyl carbamate, dimethyl hydantoin. ethylene thiourea or succinamide, the relative proportions of the active ingredients in the components being such that on mixing the entire contents of the two components a composition containing 0.5-12% by weight of the methylolated compound is obtained. The number of amino groups provided by the nitrogen containing compound may be 0.1-1 times the number of methylolated groups provided by the methylolated compound. The amount of acid polymerisation catalyst, e.g. acetic, citric, lactic, phosphoric or sulphuric acid or sodium acid phosphates, may be such that the resulting composition has a  # H of 1.5-3. The resulting composition may be in the form of a hair setting lotion.
This study reports a novel immunopotentiating effect of a lectin (FFrL) extracted from the mushroom  Fomitella fraxinea  on poultry cell-mediated immunity and poultry coccidiosis. We describe the extraction of FFrL, its in vitro mitogenic activity and in vivo protection against an oral challenge infection with  Eimeria acervulina . When tested on several cell types, crude FFrL agglutinated mouse erythrocytes and thymocytes and also various other cells including murine and human cell lines. However, crude FFrL did not agglutinate human A, B, AB, or O erythrocytes. FFrL showed a potent mitogenic activity on chicken splenic lymphocytes where at lower concentrations, crude FFrL exerted stronger mitogenic activity than Con A, a well-known potent mitogen for T lymphocytes. Further, FFrL significantly induced (P&lt;0.05) nitric oxide secretion in HD11 cells, an established macrophage cell line, and suppressed (P&lt;0.05) RP9 tumor cell growth, both, in a dose-dependent fashion. When injected into eighteen-day-old chicken embryos followed by an oral  E. acervulina  challenge infection, FFrL-treatment significantly protected chickens against weight loss associated with coccidiosis (P&lt;0.05). Injecting embryos with FFrL also resulted in significant reduction in oocyst shedding as compared to the control saline-injected birds (P&lt;0.05). The results of this study demonstrate that FFrL is an effective growth-promoting and immunostimulating agent in poultry during coccidiosis.
PURPOSE:An improver for hypoxia, containing a specific carbostyril derivative or salt thereof as an active ingredient, capable of improving the oxygen shortage state or symptoms accompanying the state and effective as an improving drug, e.g. cerebral activator, cerebrovascular disorder, etc. CONSTITUTION:An improver for hypoxia containing a carbostyril derivative expressed by formula I (R&lt;1&gt; is H, lower alkyl, etc.; R&lt;2&gt; is H or lower alkyl; R&lt;3&gt; is pyridyl or phenyl having 1-3 substituent groups, e.g. halogen, lower alkyl, etc.; formula II is a group expressed by formula III or IV; A is lower alkylene; the broken line indicates single bond or double bond, provided that R&lt;3&gt; is not pyridyl when the group expressed by formula II is a group expressed by formula IV) or a salt thereof as an active ingredient. Specifically the improver can be collectively used as a cerebral activator, consciousness disorder improving agent for cerebrovascular disorder, encephalitis, cerebral tumor, etc., drug for senile dementia, etc. The improver may be used as a drug for arrhythmia or preventing agent for cardiac failure, etc., caused by oxygen shortage.
PURPOSE:To obtain the subject substance useful as a low-toxic carcinostatic agent in high stereoselectivity and yield by reacting an epoxy alcohol derivative with a diyne compound in the presence of a base and treating the reaction product with an acid. CONSTITUTION:The objective compound of formula IV can be produced by reacting a compound of formula I (R&lt;1&gt; is tetrahydropyranyl or trialkylsilyl) with a compound of formula II (R&lt;2&gt; is same as R&lt;1&gt;; R&lt;3&gt; is ethyl, vinyl, 2- chloroethyl or 2-chloro-1-hydroxyethyl) in a solvent (e.g. THF) in the presence of a base (e.g. butyllithium) at -20-0 deg.C for 3hr and deprotecting the resultant compound of formula III with an acid (e.g. hydrochloric acid or p-toluenesulfonic acid) at 0-20 deg.C for 0.5-1hr. the compouhd of formula IV can be extracted from the rhizome or callus of Panax ginseng, however, the content is small.
PROBLEM TO BE SOLVED: To obtain a hair grower by including a specific amount of a volatile solvent, water, a pH adjustor and minoxidil so as to be excellent in the selective absorbability of the minoxidil into the hair papillae when administered to the scalp while securing the preservability of the minoxidil. SOLUTION: This hair grower is obtained by including (A) pref. 50-99 v/v% of a volatile solvent such as ethyl alcohol, (B) water, (C) a pH adjustor such as phosphoric acid and (D) pref. 0.1-5 wt.% of minoxiclil, and pref. further at least one kind of ingredient selected from 2-8C polyhydric alcohols, polyethylene glycol and fatty acid esters. It is preferable that this hair grower has &lt;=pH 4.8 when diluted ten-fold with purified water before applied to the skin; therefore the amount of the ingredient C to be formulated is pref. set at 0.01-5 wt.% based on the final hair grower.
The present invention relates to a medicine for treating Alzheimer&#39;s disease. [Solution] When adding acid, In Alzheimer&#39;s disease, amyloid β protein, which is a collection of fragments excised by two enzymes, β-sectorase and γ-sectorase, from amyloid β-precursor protein in brain cell membranes, accumulates to forms a mass called senile plaque. Since the two enzymes β-sectorase and γ-sectorase have optimum pH, the enzyme does not work if the pH value in the brain neurons is deviated from the optimum pH value. For the purpose of changing the hydrogen ion concentration, if acid is added to the brain neurons to make it acidic, the pH in the brain neurons changes and deviated from the optimum pH value. Because the two enzymes, β-sectorase and γ-sectorase, do not work, amyloid β-protein does not accumulate and senile plaques cannot be formed. When adding a base, In Alzheimer&#39;s disease, amyloid β protein, which is a collection of fragments excised by two enzymes β-sectorase and γ-sectorase from amyloid β-precursor protein in brain cell membranes, accumulates to forms a mass called senile plaque. Since the two enzymes β-sectorase and γ-sectorase have optimum pH the enzyme does not work if the pH value in the brain neurons is deviated from the optimum pH value. For the purpose of changing the hydrogen ion concentration if base is added to the brain neurons to make it basic, the pH in the brain neurons changes and deviated from the optimum pH value. Because the two enzymes, β-sectorase and γ-sectorase, do not work, amyloid β-protein does not accumulate and senile plaques cannot be formed.
Use of a LAG-3 protein or derivative thereof for the treatment of a cancer in a subject is described. In certain aspects, the subject has one or more of: a low monocyte count; a Luminal B breast cancer; an age of less than about 85 years; has been previously treated with a CDK4/6 inhibitor; has not previously undergone treatment with a taxane chemotherapy; has an elevated neutrophil to lymphocyte ratio; been diagnosed less than about 5 years ago. In another aspect, the LAG-3 protein or derivative is administered to the subject at a dosage of a molar equivalent of &gt;30 mg to &lt;120 mg of LAG-3 derivative LAG- 3Ig fusion protein IMP321. In a further aspect, the LAG-3 protein, or derivative, is administered to the subject on the same day as a chemotherapy agent. In another aspect, the LAG-3 protein, or derivative, is administered to the subject one or more times in the absence of a chemotherapy agent, after one or more dosages of the LAG-3 protein, or derivative, have been administered to the subject before, with, or after one or more dosages of the chemotherapy agent. In a further aspect, the subject is a hormone receptor-positive HER2-neg/low (HR+/HER2-neg/low) metastatic breast cancer patient, or a metastatic triple negative breast cancer (TNBC) patient.
PURPOSE:To sanitarily obtain high-purity lecithin in high yield, by extracting lipid in egg yolk with a specific mixed solvent, adding ice, fractionating and removing a water-soluble layer and treating the residual solvent layer with an ultrafiltration membrane. CONSTITUTION:A mixed solvent of an alcohol, e.g. ethanol, etc., and a nonpolar solvent, e.g. n-hexane, etc., preferably at 50/50-10/90 ratio of the alcohol to the nonpolar solvent in a volume of 1-5 times based on lecithin is added thereto and then stirred to carry out solid-liquid separation. The solvent extracting lipid containing the lecithin is recovered. Water in an amount of preferably 0.05-0.3pts.wt. based on the nonpolar solvent in the above-mentioned solvent is added to separate and remove the alcohol and the nonpolar solvent layer is passed through a solvent-resistant ultrafiltration membrane having &gt;=5,000 fractionation molecular weight to fractionate the lecithin into a neutral lipid fraction and afford the aimed high-purity lecithin.
1488859 Composition for remineralising dental enamel PROCTER &amp; GAMBLE CO 13 Nov 1974 [13 Nov 1973 10 Oct 1974] 49120/74 Heading A5B An orally-acceptable composition for remineralising dental enamel is obtained by freshly mixing (i) a first solution containing 0.005% to 5% by weight of calcium ions in the form of a water-soluble calcium salt with (ii) a second solution containing 0.005% to 5% by weight of phosphate ions in the form of a water-soluble phosphate salt or phosphoric acid, to form a metastable solution having a pH of from 2.0 to 5.0 and a molar ratio of calcium ions to phosphate ions of from 0.01:1 to 100:1. The first solution (i) may additionally contain a water-soluble salt of a polyvalent metal other than calcium e.g. Mg, Sn, Al, In, Mn, Zn, Zr, Fe, Ni, Ti, V, W, Al, Sr, Ti, and rare earth metals such as Ce, La, Sm, Pr and Nd, and the second solution (ii) may additionally contain a watersoluble salt of an anion which forms an insoluble precipitate with calcium or with said polyvalent metal e.g. a fluoride, fluorophosphate, carbonate, salt of a fatty acid having 8-18 carbons such as laurate or stearate, molybdate, sulphate, tungstate, tartrate, sorbate, alkyl sulphonate and iodate, or the second solution may also contain hydrofluoric acid. Suitable calcium salts for use in the first solution (i) are the chloride, acetate, formate, lactate and nitrate and suitable phosphate salts for the second solution (ii) are disodium hydrogen phosphate, sodium or potassium dihydrogen phosphates and trisodium phosphate. The solutions are aqueous but may also contain ethanol, glycerine or propylene glycol. The first and second solutions may be separately packaged in a kit for mixing immediately before use and such a kit may be suitable to prepare a toothpaste or a mouthwash.
[GB1488859A]
PROBLEM TO BE SOLVED: To diagnose insulin independent diabetes by immunologically measuring a specific polypeptide incident to precipitation of amyloid. SOLUTION: A tumor tissue of 2g is homogenized repeatedly in normal saline and then cleaned with distilled until soluble proteins are removed entirely. A pellet thus obtained is subjected to freeze-drying and degreased using chloroform methazole (2:1) and then treated with 6M guanidine-HCI, 0.1M, pH8.0, 0.1MDTA and 0.1 dithiothreitol. Unsolved substances are separated centrifugally and cleaned with distilled water. When a splashed sample is stained with Congo red and inspected while being polarized, it is determined that the residual substance is composed of amyloid. The used column has protein resolution of 500-60000 dalton and can separate and purify the subunit of amyloid from a patient of Langhans&#39; islet diabetes and a patient of Langhans&#39; islet independent diabetes.
The invention relates to cysteine engineered antibodies and conjugates. Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)&lt;p&gt;, wherein p is 1-4. Disclosed are applications to diagnosis and treatment by pharmaceutical compounds and compositions of the cysteine engineered antibodies.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a process for purifying immunoglobulin G from a crude immunoglobulin-containing plasma protein fraction.  &lt;P&gt;SOLUTION: In the process, anion exchange chromatography and cation exchange chromatography are preferably connected in series and an acetate buffer solution having a pH of about 5.0-6.0 and a molarity of about 5-25 mM is used throughout the purification process. The immunoglobulin product obtained by the process has a purity of higher than 98% and a content of IgG monomers and dimers of more than 98.5% and a content of IgA of less than 4 mg/l, and contains less than 0.5% of polymers and aggregates. The product does not contains a detergent, PEG or albumin as a stabilizer. The product is stable, virus-safe, liquid and ready for instant intravenous administration.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a cosmetic composition excellently stable, having excellent stability, good compatibility with the skin and an excellent touch of use without greasiness.  &lt;P&gt;SOLUTION: This cosmetic composition comprises a copolymer of hydroxyethyl acrylate or sodium acrylate and sodium acryloyldimethyltaurate as component (A), an oil as component (B) and a water-soluble thickener as component (C) or further an electrolyte or extracts containing the electrolyte as component (D). The cosmetic composition comprises the component (C) which is a carboxyvinyl polymer and/or an alkyl-modified carboxyvinyl polymer. The cosmetic composition comprises the component (B) that is a silicone oil and/or an oil which is a liquid at room temperature. The cosmetic composition comprises the surfactant in ≤1/10 ratio of the oil expressed in terms of mass ratio. The cosmetic composition has low irritation.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
PURPOSE:An immunological regulator, containing a physiological active substance beta-alanine or a salt thereof as an active constituent, having immunological regulating action even on restoration of lesion tissues which is not found in the conventional immunological regulators and useful for immunological abnormality such as serum disease or rheumatism. CONSTITUTION:An immunological regulator containing beta-alanine expressed by the formula H2NCH2CH2COOH or a salt thereof as an active constituent. The beta-alanine is a physiologically active substance present in animal or plant tissues, and it has lately been found that the beta-alanine has improved immunological regulating action and is useful as an immunological regulator. The beta-alanine has the immunological regulating action even on the restoration of lesion tissues and is used nonspecifically for diseases of immunological abnormality, e.g. lupus erythematosus, mixed type cryoglobulinemia, collagenosis or Behcet&#39;s disease. The above-mentioned regulator may be orally or parenterally adminiatered, has high safety and can be used without fear for side effects.
FIELD: radioisotopic diagnosis, pharmacy. SUBSTANCE: method involves preparing the colloidal solution of rhenium sulfide labeled with To-98m (KOPEH) and its binding with human serum albumin and saline solution up to the final albumin concentration 3.0-3.5% and volume activity 34-42 MBk in 1 ml. Binding the known preparation (KOPEH) with human serum albumin ensures to obtain preparation exhibiting the stable colloidal-opsonine links with carrier - human albumin molecules. The proposed preparation is released from &#34;tissue depot&#34; at the increased velocity as compared with that of the known one. Preparation shows the constant accumulation rate in lymphonodules. EFFECT: improved quality, enhanced lymphotropic property, decreased radiation loading.
PURPOSE:To obtain a thromboxane A2 antagonist having low toxicity and high safety and useful as a platelet coagulation suppressing agent by using a phenoxyacetic acid derivative as an active component. CONSTITUTION:The objective agent can be prepared by using a compound of formula (R&lt;1&gt; to R&lt;4&gt; and R&lt;7&gt; are H or lower alkyl; R&lt;5&gt; is (substituted) phenyl; R&lt;6&gt; is (protected) carboxyl or OH; ring A is substituted phenylene; (m) is 0 or 1; (n) is 0-5; etc.) or its salt as an essential component, properly mixing the component with conventional drug preparation raw materials and forming the mixture in a drug form by conventional procedure. It can be used in the form of tablet, granule, capsule, suspension, emulsion, injection, etc. The daily dose of the agent is 0.01-50mg/kg. Useful for the therapy, amelioration and prevention of various diseases such as thrombosis and embolism, prevention of thrombosis in the extracorporeal circulation of blood, administration in the case of organ transplantation, therapy amelioration and prevention of myocardial ischemia, instable stenocardia, etc.
The invention discloses a 2,7-naphthyridine derivative and a preparation method and application thereof. The derivative is a compound with a structure represented by the formula I, or a pharmaceutically acceptable equivalent or salt thereof. The compound represented by the formula has a good inhibiting effect against various kinase activities. Half inhibitory concentrations of the compound against kinases such as c-Met, KDR, c-kit, and the like are generally lower than 10&lt;-7&gt;mol.L&lt;-1&gt;. Also, according to the embodiment of the invention, the compound with the structure of the formula I has an inhibiting effect against the proliferation of various tumor cells. The formula I is represented as the following.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a sheet to be stuck on the skin, usable as a drug, an unregulated drug or the like by being stuck on the prescribed site of the skin, making the absorption of an active ingredient good, having excellent transcutaneous absorption effects as a drug or the like, and hardly reducing the adhesive force of a base material.  &lt;P&gt;SOLUTION: This sheet to be stuck on the skin is obtained by sealing an impregnated material 2 impregnated with a liquid with a packaging material 3 comprising an upper sheet 4 and a lower sheet 5. The package material 3 having the sealed impregnated material 2 is formed on a base material 1. At least the skin-contacting surface side of the impregnated material 2 is covered with a release-regulating film 8 capable of gradually releasing the liquid included in the impregnated material 1. The package material 3 is constituted so as to be open by peeling the upper sheet 4 from the lower sheet 5.  &lt;P&gt;COPYRIGHT: (C)2003,JPO